Skip to main content

Table 1 Patient and tumor characteristics

From: Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: initial clinical results

  No. of patients
(n = 9)
Age, y, median (range) 68 (44–86)
Sex, n (%)
 Male 3 (33.3)
 Female 6 (66.7)
ECOGa performance status, n (%)
 0 3 (33.3)
 1 6 (66.7)
Tumor size, mm, median (range) 34 (21–60)
Tumor invasion, n (%)
 Celiac artery 8 (88.9)
 Common hepatic artery 9 (100)
 Superior mesenteric artery 1 (11.1)
 Splenic artery 9 (100)
 Portal vein 6 (66.7)
 Splenic vein 8 (88.9)
 Anterior peripancreatic tissue 5 (55.6)
 Posterior peripancreatic tissue 9 (100)
UICC TNM classificationb, n (%)
 T4N0M0 4 (44.4)
 T4N1M0 5 (55.6)
Postoperative serum laboratory data
 Albumin g/dl, median (range) 4.0 (3.7–4.4)
 Pancreas-amylase IU/I, median (range) 47 (8–172)
 Lipase IU/I, median (range) 33 (15–138)
 CEA ng/ml, median (range) 2.0 (0.8–5.1)
 CA19-9 U/ml, median (range) 127 (1–3267)
  1. aEastern Cooperative Oncology Group
  2. bUnion for International Cancer Control (UICC) tumor-node-metastasis (TNM) classification 8th edition
  3. CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19–9